Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302143 | 0.92 | MAPT (0.54) | HTR6RORCMEN1KMT2AMAPT | |
| SCHEMBL18363030 | 0.90 | TP53 (0.62) | HTR6MEN1KMT2ATP53MAPT | |
| SCHEMBL772020 | 0.87 | RORC (0.61) | HTR6RORCMEN1KMT2A | |
| SCHEMBL26005660 | 0.81 | MAPT (0.63) | HTR6TP53MAPTLMNACYP11B1 | |
| SCHEMBL18363031 | 0.81 | KMT2A (0.73) | MEN1KMT2AATMTP53MAPT | |
| SCHEMBL10178084 | 0.80 | HTR6 (0.54) | HTR6RORCMEN1KMT2AATM | |
| SCHEMBL31456270 | 0.79 | MEN1 (0.62) | RORCMEN1KMT2ATP53MAPT | |
| SCHEMBL16794469 | 0.78 | HTR6 (0.50) | HTR6MEN1KMT2ATP53MAPT | |
| SCHEMBL29676616 | 0.78 | HTR6 (0.50) | HTR6MEN1KMT2ATP53MAPT | |
| SCHEMBL12744009 | 0.78 | MAPT (0.58) | RORCMEN1KMT2AATMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459002-A | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2017-02-22 | — | — | CN | disclosed |